Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Otila Dumetrescu"'
Autor:
Barbara Grant, Andrew D. Zelenetz, A. Dimitrios Colevas, Paul A. Hamlin, Carol S. Portlock, Michael D. Stubblefield, David J. Straus, Craig H. Moskowitz, Otila Dumetrescu, Owen A. O'Connor
Publikováno v:
British journal of haematology. 143(2)
The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd343e71a64bcf20002e389c5d1faa3
https://pubmed.ncbi.nlm.nih.gov/18691173
https://pubmed.ncbi.nlm.nih.gov/18691173
Autor:
Debra M. Sarasohn, Andrew D. Zelenetz, Martin Fleischer, Otila Dumetrescu, Barbara MacGregor-Cortelli, Craig H. Moskowitz, Diane R. Mould, Steven M. Horwitz, Ariela Noy, Paul A. Hamlin, Frank Sirotnak, Owen A. O'Connor, David J. Straus, Ellen Neylon, Carol S. Portlock
Publikováno v:
British journal of haematology. 139(3)
T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264fdc7fe0f6b691ad7664e439406332
https://pubmed.ncbi.nlm.nih.gov/17910632
https://pubmed.ncbi.nlm.nih.gov/17910632
Autor:
Owen A. O'Connor, Elizabeth Trehu, David J. Straus, Michael D. Stubblefield, John J. Wright, Jamie Muzzy, Paul A. Hamlin, Otila Dumetrescu, Dixie Lee Esseltine, Julian Adams, Carol S. Portlock, Craig H. Moskowitz, Andrew D. Zelenetz, Barbara MacGregor-Cortelli, David P. Schenkein, Elizabeth Choi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(4)
Purpose To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL). Patients and Methods Patients with indolent and MCL were eligible. Bortezomib was given at a dose of 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5f9c05f6f29978e44456c76709e170
https://pubmed.ncbi.nlm.nih.gov/16130931
https://pubmed.ncbi.nlm.nih.gov/16130931
Autor:
J. Pappanicolou, Diane R. Mould, Paul A. Hamlin, Ariela Noy, Martin Fleischer, Otila Dumetrescu, John F. Gerecitano, Debra M. Sarasohn, Chaya S. Moskowitz, Andrew D. Zelenetz, Frank Sirotnak, Ellen Neylon, Owen A. O'Connor, Steve Horwitz, David J. Straus, Carol S. Portlock, Michael Saunders
Publikováno v:
Blood. 108:400-400
T-cell lymphomas (TCL) represent a diverse and heterogeneous group of diseases. The prognosis of patients with TCL is generally much worse than for patients with B-cell lymphoma (BCL). Pralatrexate is a novel 10-deazaminopoterin rationally designed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3286b07ffd73ac8ebc69262ae3402be1
https://doi.org/10.1182/blood.v108.11.400.400
https://doi.org/10.1182/blood.v108.11.400.400